Affymetrix Divests Western Blot Products
The divestiture is in accordance with Affymetrix’s transition to serving translational and clinical markets, which offer higher growth opportunities. The acquisition expands Rockland’s Western blot offerings.
Gilbertsville, PA 12/13/12—Rockland Immunochemicals, a provider of antibodies and antibody-based tools, has acquired the TrueBlot IP (immunoprecipitation)/Western blot product line from eBiosciences, an Affymetrix company. “As eBioscience continues to focus its efforts on our evolving flow cytometry, immunoassay and immunohistochemistry applications in immunology, oncology and other therapeutic areas, we are pleased that the TrueBlot product line is a strong strategic fit for the Rockland portfolio,” stated Don Tartre, general manager of eBioscience.
